Nicotine Dependence, Cigarettes Clinical Trial
— INITIATEOfficial title:
The INITIATE Study: Initiating Nicotine Dependence Treatment for Smokers Admitted to Emergency Departments
Verified date | January 2024 |
Source | Ottawa Heart Institute Research Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The INITIATE Study is a randomized controlled trial that is testing an intervention designed to increase long-term abstinence among tobacco smokers seen in emergency departments (ED). The intervention includes a behavioural incentive and tailored follow-up support on long-term smoking abstinence, health, healthcare utilization, and cost. Tobacco-related illnesses cost the healthcare system millions each year. Quitting smoking improves smoking-related outcomes, like the onset or management of heart disease, stroke, lung diseases, and several cancers. There are approximately 16 million visits to Canadian EDs each year; an estimated 3-4 million of these involve smokers. Effective quit smoking interventions exist, but are underutilized. Few hospital EDs in Canada offer tobacco-use interventions. In order for ED staff to offer quit smoking support, interventions need to be simple given the realities of the ED environment. Considering that stopping smoking improves health outcomes, that tobacco-use is an important cause of preventable ED use, and the volume of smokers, Canadian EDs are a missed opportunity in the initiation of quit smoking support. Our intervention has been designed to optimize uptake and smoking abstinence by including the most effective evidence-based behavioural and drug-related approaches, removing specific barriers and challenges that smokers face when trying to quit (e.g., affordability, low confidence and motivation), while packaging the intervention in a quick-to-initiate manner, making it ideal for fast-paced, complex ED environments.
Status | Active, not recruiting |
Enrollment | 1208 |
Est. completion date | November 2026 |
Est. primary completion date | August 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Current daily smoker (smokes = 5 cigarettes per day); - = 18 years of age (the age of majority in Ontario); - Assigned a CTAS level of 2-5 (emergent to non-urgent); - Able to read and understand English or French; - Resides in Ontario and eligible for Ontario Health Insurance Plan (to permit linkage with administrative data housed at the Institute for Clinical Evaluative Sciences [ICES]); - Available and willing to participate in follow-up assessments over the next 24 months; - Has access to a telephone or computer; - Able to provide informed consent Exclusion Criteria: - Currently participating in this or another smoking cessation study; - Assigned a CTAS level of 1 (resuscitation - the most seriously ill patients with highest likelihood of hospital admission) or in psychiatric emergency unit; - Pregnant, planning to become pregnant over the next 2 years, or breastfeeding; - Has morbid illness which will prevent completion of 26-week follow-up (e.g., receiving palliative care); - In the opinion of the ED physician, manifests acute physical and/or psychiatric illness or has cognitive impairment that would preclude participation in/benefit from the intervention. |
Country | Name | City | State |
---|---|---|---|
Canada | The Ottawa Hospital Civic Campus | Ottawa | Ontario |
Canada | The Ottawa Hospital General Campus | Ottawa | Ontario |
Lead Sponsor | Collaborator |
---|---|
Ottawa Heart Institute Research Corporation | Canadian Institutes of Health Research (CIHR) |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Smoking Abstinence | Smoking abstinence at 26 weeks, biochemically verified using an expired air carbon monoxide (CO) test | 26 weeks (6 months) after study enrollment | |
Secondary | Prolonged Abstinence | Prolonged (since last time point) smoking abstinence, at 4, 26, 52 and 104 weeks | 4, 26, 52 and 104 weeks after study enrollment | |
Secondary | Point Prevalence Abstinence | Point prevalence smoking abstinence, at 4, 52 and 104 weeks | 4, 52 and 104 weeks after study enrollment | |
Secondary | Smoking Reduction | Smoking reduction (i.e., change in number of daily cigarettes), at 4, 26, 52 and 104 weeks | 4, 26, 52 and 104 weeks after study enrollment | |
Secondary | Number of Quit Attempts | Number of quit attempts since study entry, at 4, 26, 52 and 104 weeks | 4, 26, 52 and 104 weeks after study enrollment | |
Secondary | Cessation Medication and/or E-cigarette Use | Use of smoking cessation medication and/or e-cigarette, at 4, 26, 52 and 104 weeks | 4, 26, 52 and 104 weeks after study enrollment | |
Secondary | Use of Behavioural Supports | Use of behavioural supports (e.g., counseling, quit lines), at 4, 26, 52 and 104 weeks | 4, 26, 52 and 104 weeks after study enrollment | |
Secondary | Health-Related Quality of Life | Health-related quality of life (HR-QoL), at 52 and 104 weeks. This will be measured using the 36-Item Short Form Health Survey (SF-36), where each item is scored so that the lowest and highest possible scores are 0 and 100 respectively, and a high score outlines a more favorable state of health. | 52 and 104 weeks after study enrollment | |
Secondary | Health Services Outcomes - ED visits | Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) visits to ED at 4, 26, 52 and 104 weeks | 4, 26, 52 and 104 weeks after study enrollment | |
Secondary | Health Services Outcomes - Hospital Admissions | Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) admissions to hospital at 4, 26, 52 and 104 weeks | 4, 26, 52 and 104 weeks after study enrollment | |
Secondary | Health Services Outcomes - Deaths | Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) deaths at 4, 26, 52 and 104 weeks | 4, 26, 52 and 104 weeks after study enrollment | |
Secondary | Cost-Effectiveness Ratios | Cost-effectiveness ratios related to health services at 52 and 104 weeks | 52 and 104 weeks after study enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05477342 -
Reducing Nicotine Addiction in Adolescent Smokers
|
N/A | |
Completed |
NCT03011710 -
Epidemiology and Acute Oral Effects Electronic Cigarette
|
N/A | |
Recruiting |
NCT03194919 -
Negotiating a Quit Date or Not in Online Interventions
|
N/A | |
Recruiting |
NCT03191825 -
Online Lapse Management Intervention
|
N/A | |
Completed |
NCT03719391 -
United States Pre-Market Tobacco Application Pharmacokinetics
|
N/A | |
Completed |
NCT05538702 -
Acute Oral Effects of Heated Tobacco Products
|
N/A | |
Completed |
NCT02723162 -
Translational Neuropsychopharmacology Research of Nicotine Addiction
|
Phase 2 | |
Completed |
NCT03194958 -
Helping Poor Smokers Quit
|
N/A | |
Completed |
NCT03593239 -
Comparing the Pharmacokinetics of Nicotine Salt Based ENDS in Healthy Smokers
|
N/A | |
Completed |
NCT04830384 -
Evaluation of LLLT/Music for Smoking Cessation
|
N/A | |
Completed |
NCT02367391 -
Penn State TXT2Quit Study
|
N/A | |
Recruiting |
NCT05665465 -
Neurobehavioral Mechanisms Linking Childhood Adversity to Increased Risk for Smoking
|
Early Phase 1 | |
Completed |
NCT04805515 -
Impact of Nicotine Messaging on Nicotine Beliefs and Tobacco Use Behavior
|
N/A | |
Completed |
NCT03700112 -
Clinical Study Comparing 7 ENDS Products and 1 Combustible Cigarette Using 2 Delivery Methods.
|
N/A | |
Terminated |
NCT02986711 -
Penn State TXT2STAYQUIT Study- a Texting Study to Help Hospitalized Smokers Stay Quit
|
N/A | |
Recruiting |
NCT05224154 -
Re-Connect Application for Smoking Cessation
|
N/A | |
Completed |
NCT03492463 -
The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion Products
|
Phase 2 | |
Withdrawn |
NCT03473483 -
Cigarette Harm Reduction With Electronic Cigarette Use
|
N/A | |
Completed |
NCT04379388 -
Improving Smoking Cessation in Socioeconomically-Disadvantaged Young Adults
|
N/A |